FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma

02/02/2021 By Dr. Dan Platt

Summary: The Food and Drug Administration (FDA) has announced the approval of a new therapy combination for relapsed or refractory multiple myeloma. The combination of carfilzomib (Kyprolis), daratumumab (Darzalex), and dexamethasone (steroid) is now approved for use in patients who have received one to three prior lines of treatment.

Dr. Dan’s Takeaway: These drugs were all previously approved for relapsed or refractory multiple myeloma and have proven effectiveness and safety. This particular combination was already being used by oncologists, but now has explicit FDA support and positive data that supports its role as another treatment option.



Deskside with Dr. Dan

“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

– Dan Platt, M.D.

Chief Medical Officer

About The Poster

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore the latest Hub posts


Top Tips for Dealing with Holiday Blues

Many people deal with the holiday blues, including several of our team members! The Gryt Health team came together to create this piece with some of our favorite tips and tricks for dealing with the Holiday Blues!

Tell Your Story

Irene’s Stomach Cancer Story

Gryt Health Community Member, Irene shares the start of her journey with Stomach Cancer.

Want Email Updates?

Get updates in your inbox when new content is posted on the website.

Find value in this post? Please share!

You are never alone

View our resources for those who are experiencing, have experienced, or are supporting someone who has experienced a medical diagnosis.